Current and historical daily PE Ratio for Santen Pharmaceutical Co Ltd (
FRA:SZD
) from 1990 to Jun 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Santen Pharmaceutical stock (FRA:SZD) PE ratio as of Jun 24 2024 is 21.85.
More Details
Santen Pharmaceutical Co Ltd (FRA:SZD) PE Ratio (TTM) Chart
Santen Pharmaceutical Co Ltd (FRA:SZD) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1264
- 1
- 2
- 3
- 4
- 5
- 6
- 15
Santen Pharmaceutical PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-25 | 19.8 | 2024-04-19 | 18.6 |
2024-06-21 | 19.8 | 2024-04-18 | 18.4 |
2024-06-20 | 19.9 | 2024-04-17 | 18.6 |
2024-06-19 | 19.5 | 2024-04-16 | 18.5 |
2024-06-18 | 19.4 | 2024-04-15 | 18.5 |
2024-06-17 | 19.9 | 2024-04-12 | 18.6 |
2024-06-14 | 19.8 | 2024-04-11 | 18.5 |
2024-06-13 | 19.4 | 2024-04-10 | 18.5 |
2024-06-12 | 19.8 | 2024-04-09 | 18.5 |
2024-06-11 | 20.2 | 2024-04-08 | 18.4 |
2024-06-10 | 20.2 | 2024-04-05 | 19.1 |
2024-06-07 | 20.0 | 2024-04-04 | 18.5 |
2024-06-06 | 20.6 | 2024-04-03 | 18.5 |
2024-06-05 | 20.4 | 2024-04-02 | 18.6 |
2024-06-04 | 20.3 | 2024-03-28 | 19.1 |
2024-06-03 | 20.2 | 2024-03-27 | 18.7 |
2024-05-31 | 20.1 | 2024-03-26 | 18.4 |
2024-05-30 | 20.5 | 2024-03-25 | 18.1 |
2024-05-29 | 19.9 | 2024-03-22 | 18.3 |
2024-05-28 | 20.0 | 2024-03-21 | 17.9 |
2024-05-27 | 19.6 | 2024-03-20 | 17.7 |
2024-05-24 | 19.2 | 2024-03-19 | 18.1 |
2024-05-23 | 19.1 | 2024-03-18 | 17.8 |
2024-05-22 | 19.3 | 2024-03-15 | 18.2 |
2024-05-21 | 19.2 | 2024-03-14 | 18.1 |
2024-05-20 | 19.4 | 2024-03-13 | 18.2 |
2024-05-17 | 19.9 | 2024-03-12 | 18.7 |
2024-05-16 | 20.4 | 2024-03-11 | 18.3 |
2024-05-15 | 20.0 | 2024-03-08 | 18.2 |
2024-05-14 | 20.1 | 2024-03-07 | 18.5 |
2024-05-13 | 20.7 | 2024-03-06 | 18.5 |
2024-05-10 | 20.5 | 2024-03-05 | 18.3 |
2024-05-09 | 20.1 | 2024-03-04 | 18.5 |
2024-05-08 | 19.5 | 2024-03-01 | 18.6 |
2024-05-07 | 19.3 | 2024-02-29 | 18.6 |
2024-05-06 | 19.3 | 2024-02-28 | 18.8 |
2024-05-03 | 19.5 | 2024-02-27 | 19.3 |
2024-05-02 | 20.0 | 2024-02-26 | 19.5 |
2024-04-30 | 19.1 | 2024-02-23 | 18.9 |
2024-04-29 | 18.9 | 2024-02-22 | 19.3 |
2024-04-26 | 18.8 | 2024-02-21 | 19.2 |
2024-04-25 | 18.8 | 2024-02-20 | 19.0 |
2024-04-24 | 19.0 | 2024-02-19 | 19.3 |
2024-04-23 | 19.2 | 2024-02-16 | 19.9 |
2024-04-22 | 18.7 | 2024-02-15 | 19.5 |
Santen Pharmaceutical Co Ltd (FRA:SZD) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Santen Pharmaceutical Co Ltd
NAICS : 325412
ISIN : JP3336000009
Share Class Description:
FRA:SZD: Ordinary SharesDescription
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.